fenofibrate has been researched along with Impaired Glucose Tolerance in 9 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our study included 41 fenofibrate-treated patients with impaired glucose tolerance allocated to either metformin (3 g daily) or placebo." | 9.17 | Effect of metformin on selected parameters of hemostasis in fenofibrate-treated patients with impaired glucose tolerance. ( Gdula-Dymek, A; Krysiak, R; Okopień, B, 2013) |
| "The study included 80 patients with isolated impaired glucose tolerance and normal plasma lipids who complied with lifestyle modifications and received chronic fenofibrate treatment." | 9.17 | Lymphocyte-suppressing, endothelial-protective and systemic anti-inflammatory effects of metformin in fenofibrate-treated patients with impaired glucose tolerance. ( Gdula-Dymek, A; Krysiak, R; Okopień, B, 2013) |
| "The study included 43 patients with isolated impaired glucose tolerance and normal plasma lipids who had been treated for at least 6 months with micronized fenofibrate (200 mg daily)." | 9.17 | Monocyte-suppressing effect of high-dose metformin in fenofibrate-treated patients with impaired glucose tolerance. ( Gdula-Dymek, A; Krysiak, R; Okopień, B, 2013) |
| "This was a prospective, randomized, placebo-controlled trial involving the group of 91 ambulatory patients with impaired glucose tolerance (IGT) (diagnosed on the basis of the American Diabetes Association criteria), randomly divided into three groups, simultaneously treated for 30 d with the AHA step 1 diet (n = 30), micronized fenofibrate (267 mg/d, n = 31), or placebo (n = 30)." | 9.12 | Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance. ( Herman, ZS; Krysiak, R; Okopień, B, 2006) |
| " Ten adolescents with hyperinsulinemia and dyslipidemia received therapy with metformin (500-1500 mg/daily) and micronized fenofibrate (160 mg/daily)." | 7.81 | Carbohydrate-lipid profile and use of metformin with micronized fenofibrate in reducing metabolic consequences of craniopharyngioma treatment in children: single institution experience. ( Kalina, MA; Kalina-Faska, B; Mandera, M; Małecka Tendera, E; Skała-Zamorowska, E; Wilczek, M, 2015) |
| "Fifty-eight patients with impaired fasting glucose (IFG), fifty-six subjects with impaired glucose tolerance (IGT) and fifty-five normolipidemic control subjects with asymptomatic atherosclerosis, were treated for 90 days with either micronized fenofibrate (200 mg/day) or placebo." | 7.76 | The effect of fenofibrate on lymphocyte cytokine release in patients with impaired fasting glucose and impaired glucose tolerance: a preliminary report. ( Krysiak, R; Okopien, B, 2010) |
| "Our study included 41 fenofibrate-treated patients with impaired glucose tolerance allocated to either metformin (3 g daily) or placebo." | 5.17 | Effect of metformin on selected parameters of hemostasis in fenofibrate-treated patients with impaired glucose tolerance. ( Gdula-Dymek, A; Krysiak, R; Okopień, B, 2013) |
| "The study included 80 patients with isolated impaired glucose tolerance and normal plasma lipids who complied with lifestyle modifications and received chronic fenofibrate treatment." | 5.17 | Lymphocyte-suppressing, endothelial-protective and systemic anti-inflammatory effects of metformin in fenofibrate-treated patients with impaired glucose tolerance. ( Gdula-Dymek, A; Krysiak, R; Okopień, B, 2013) |
| "The study included 43 patients with isolated impaired glucose tolerance and normal plasma lipids who had been treated for at least 6 months with micronized fenofibrate (200 mg daily)." | 5.17 | Monocyte-suppressing effect of high-dose metformin in fenofibrate-treated patients with impaired glucose tolerance. ( Gdula-Dymek, A; Krysiak, R; Okopień, B, 2013) |
| "This was a prospective, randomized, placebo-controlled trial involving the group of 91 ambulatory patients with impaired glucose tolerance (IGT) (diagnosed on the basis of the American Diabetes Association criteria), randomly divided into three groups, simultaneously treated for 30 d with the AHA step 1 diet (n = 30), micronized fenofibrate (267 mg/d, n = 31), or placebo (n = 30)." | 5.12 | Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance. ( Herman, ZS; Krysiak, R; Okopień, B, 2006) |
| " Ten adolescents with hyperinsulinemia and dyslipidemia received therapy with metformin (500-1500 mg/daily) and micronized fenofibrate (160 mg/daily)." | 3.81 | Carbohydrate-lipid profile and use of metformin with micronized fenofibrate in reducing metabolic consequences of craniopharyngioma treatment in children: single institution experience. ( Kalina, MA; Kalina-Faska, B; Mandera, M; Małecka Tendera, E; Skała-Zamorowska, E; Wilczek, M, 2015) |
| "Fifty-eight patients with impaired fasting glucose (IFG), fifty-six subjects with impaired glucose tolerance (IGT) and fifty-five normolipidemic control subjects with asymptomatic atherosclerosis, were treated for 90 days with either micronized fenofibrate (200 mg/day) or placebo." | 3.76 | The effect of fenofibrate on lymphocyte cytokine release in patients with impaired fasting glucose and impaired glucose tolerance: a preliminary report. ( Krysiak, R; Okopien, B, 2010) |
| " These mice had an obese body, lipid metabolic disorder and insulin resistance and were treated orally with 100 mg/kg/day 3'-deoxyadenosine (DA), 15 mg/kg/day rosiglitazone and 150 mg/kg/day fenofibrate, respectively." | 3.76 | Improvement on lipid metabolic disorder by 3'-deoxyadenosine in high-fat-diet-induced fatty mice. ( Liu, Q; Niu, YJ; Tao, RY; Tian, JY; Ye, F; Zhu, HB; Zhu, P, 2010) |
| "In Ppara-null mice, MFD treatment increased body weight, adipose tissue, serum TG and impaired glucose tolerance." | 1.48 | PPARα-independent action against metabolic syndrome development by fibrates is mediated by inhibition of STAT3 signalling. ( Dai, M; Gonzalez, FJ; Hua, H; Huang, J; Lin, H; Liu, A; Liu, L; Wang, F; Xi, Y; Xu, G; Yang, J; Zhao, T, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 7 (77.78) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hua, H | 1 |
| Yang, J | 1 |
| Lin, H | 1 |
| Xi, Y | 1 |
| Dai, M | 1 |
| Xu, G | 1 |
| Wang, F | 1 |
| Liu, L | 1 |
| Zhao, T | 1 |
| Huang, J | 1 |
| Gonzalez, FJ | 1 |
| Liu, A | 1 |
| Krysiak, R | 5 |
| Gdula-Dymek, A | 3 |
| Okopień, B | 5 |
| Kalina, MA | 1 |
| Wilczek, M | 1 |
| Kalina-Faska, B | 1 |
| Skała-Zamorowska, E | 1 |
| Mandera, M | 1 |
| Małecka Tendera, E | 1 |
| Niu, YJ | 1 |
| Tao, RY | 1 |
| Liu, Q | 1 |
| Tian, JY | 1 |
| Ye, F | 1 |
| Zhu, P | 1 |
| Zhu, HB | 1 |
| Herman, ZS | 1 |
| Haffner, SM | 1 |
| Ashraf, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Acute or Chronic Ingestion of Sucralose on Serum Insulin in Young and Healthy Adults: a Randomized, Double-blind, Placebo-controlled Trial[NCT03703141] | 95 participants (Actual) | Interventional | 2016-09-27 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 trials available for fenofibrate and Impaired Glucose Tolerance
| Article | Year |
|---|---|
Effect of metformin on selected parameters of hemostasis in fenofibrate-treated patients with impaired glucose tolerance.
Topics: Dose-Response Relationship, Drug; Drug Synergism; Female; Fenofibrate; Fibrinogen; Glucose Intoleran | 2013 |
Lymphocyte-suppressing, endothelial-protective and systemic anti-inflammatory effects of metformin in fenofibrate-treated patients with impaired glucose tolerance.
Topics: Anti-Inflammatory Agents; C-Reactive Protein; Cytokines; Drug Therapy, Combination; Female; Fenofibr | 2013 |
Monocyte-suppressing effect of high-dose metformin in fenofibrate-treated patients with impaired glucose tolerance.
Topics: Adult; Aged; Anti-Inflammatory Agents; Biomarkers; Blood Glucose; C-Reactive Protein; Cytokines; Fem | 2013 |
Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance.
Topics: Adult; Biomarkers; Blood Glucose; Cytokines; Diet; Female; Fenofibrate; Fibrinogen; Glucose Intolera | 2006 |
5 other studies available for fenofibrate and Impaired Glucose Tolerance
| Article | Year |
|---|---|
PPARα-independent action against metabolic syndrome development by fibrates is mediated by inhibition of STAT3 signalling.
Topics: 3T3-L1 Cells; Adipose Tissue; Animals; Body Weight; Fenofibrate; Fibric Acids; Gemfibrozil; Glucose | 2018 |
Carbohydrate-lipid profile and use of metformin with micronized fenofibrate in reducing metabolic consequences of craniopharyngioma treatment in children: single institution experience.
Topics: Adolescent; Carbohydrates; Child; Child, Preschool; Craniopharyngioma; Dyslipidemias; Female; Fenofi | 2015 |
The effect of fenofibrate on lymphocyte cytokine release in patients with impaired fasting glucose and impaired glucose tolerance: a preliminary report.
Topics: Adult; Aged; Atherosclerosis; Cytokines; Female; Fenofibrate; Glucose; Glucose Intolerance; Glucose | 2010 |
Improvement on lipid metabolic disorder by 3'-deoxyadenosine in high-fat-diet-induced fatty mice.
Topics: Animals; Area Under Curve; Cordyceps; Deoxyadenosines; Dietary Fats; Disease Models, Animal; Fenofib | 2010 |
Predicting risk reduction of coronary disease in patients who are glucose intolerant: a comparison of treatment with fenofibrate and other lipid-modifying agents.
Topics: Coronary Disease; Cost Savings; Cost-Benefit Analysis; Fenofibrate; Glucose Intolerance; Humans; Hyd | 2000 |